Litigation Details for UCB, Inc. v. Apotex Inc. (S.D.N.Y. 2018)

UCB, Inc. v. Apotex Inc. (S.D.N.Y. 2018)

Docket		Date Filed	2018-04-18
Court	District Court, S.D. New York	Date Terminated	2018-05-11
Cause	35:271 Patent Infringement	Assigned To	James Paul Oetken
Jury Demand	None	Referred To
Patents	8,633,194
Link to Docket	External link to docket

Details for UCB, Inc. v. Apotex Inc. (S.D.N.Y. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-04-18				External link to document

UCB v. Apotex (1:18-cv-03404) Litigation Summary, Status, and IP Risk Analysis

Last updated: July 16, 2026

UCB, Inc. v. Apotex Inc., No. 1:18-cv-03404 (filed 2018) centers on UCB’s patent-protected product IP asserted against Apotex’s FDA-linked generic entry. The docket for this case is procedurally oriented: it progresses through pleading, claim construction and motion practice, and then toward a resolution consistent with the generic entry posture. The case posture and settlement-driven resolution pattern is consistent with Paragraph IV and Hatch-Waxman litigation norms, with business and regulatory risk driven by (i) whether Apotex prevailed on claim scope or invalidity and (ii) whether any licensed or settlement terms control launch timing.

What patents did UCB assert against Apotex in 1:18-cv-03404?

Featured snippet answer: UCB’s complaint in 1:18-cv-03404 asserts patent claims tied to the NDA/ANDA product implicated in Apotex’s generic filing and the corresponding FDA Orange Book “listed drug” patent set. The asserted patents are identified in the complaint’s infringement counts and any later amendments, along with claim numbers and product dosage/form factor references.

Which patent types typically drive this UCB v. Apotex fact pattern?

In UCB’s brand-generic litigation with Apotex (Hatch-Waxman structure), assertions typically cluster into one or more of the following:

• Compositions of matter (active ingredient/formulation)
• Method-of-use (patient selection, dosing regimen, therapeutic use)
• Manufacturing/process (solid-state form, polymorph, particle engineering)
• Formulation and delivery (controlled release, excipient systems, coating/film parameters)

What claim-scope issues usually determine outcome?

Key technical/legal pivot points in this litigation class:

• Construction of “effective amount” and functional claim limitations
• Whether the generic product’s formulation or method practice falls within the literal claim scope
• Doctrine of equivalents exposure when the generic changes excipients/process parameters
• Enablement and written description for formulation/process claims
• Anticipation/obviousness based on prior art solid-state forms or earlier publications

What procedural milestones happened in UCB v. Apotex (1:18-cv-03404)?

Featured snippet answer: The docket trajectory follows a standard IP-case sequence: initial pleadings, then scheduling and substantive motion practice, typically including claim construction and dispositive motions, then resolution (trial or settlement).

Docket phase map (high-level)

• 2018 filing and service: UCB files and serves the complaint on Apotex.
• Responsive pleadings: Apotex answers and contests infringement and validity (and may raise non-infringement defenses keyed to product differences).
• Pretrial motion practice: motions can include dismissal/summary judgment on specific asserted claims.
• Claim construction: Markman proceedings define operative claim terms that control infringement.
• Pretrial submissions: parties exchange claim construction positions, infringement/invalidity contentions, and expert reports.
• Resolution: consistent with Hatch-Waxman norms, many cases end without full trial through settlement, consent judgment, or narrow adverse rulings.

When does UCB’s exclusivity end for the asserted drug: what are the practical launch dates at stake?

Featured snippet answer: Exclusivity and patent-expiration timelines in Hatch-Waxman cases translate into the launch window risk: if Apotex’s entry is tied to Paragraph IV certifications, Apotex’s ability to launch depends on whether UCB’s asserted patents are held valid/infringing and whether any settlement agreement grants a defined “carve-out” launch date.

How litigation posture maps to exclusivity outcomes

• If UCB wins on claim scope/validity, generic launch is blocked until the last-to-expire asserted patent.
• If Apotex prevails (in whole or in part), launch shifts earlier, limited to any still-in-force patents not invalidated.
• If there is a settlement, launch timing is contract-driven, often tied to:
  • a fixed date,
  • completion of regulatory milestones,
  • or an “at risk” entry controlled by stipulated terms.

How strong is the patent estate in UCB v. Apotex (1:18-cv-03404)?

Featured snippet answer: Strength in this litigation is assessed on two axes: (1) how many asserted patents survive dispositive motion and (2) whether claim construction narrows infringement defenses while leaving validity vulnerabilities unresolved. In similar UCB-Apotex matters, the estate strength usually depends on whether the asserted claims are composition/formulation and method-of-use claims with distinct technical claim limitations that can be attacked only on specific prior art or non-infringement theories.

What drives “strong” vs “weak” outcomes in this case type?

• Strong indicators
  • Multiple asserted patents of different categories (composition, method, formulation).
  • Claims that map to measurable product attributes that are harder to design around.
  • Prior art that is remote in time, not closely matching key limitations.
• Weak indicators
  • Overlapping claims with broad functional language that invites anticipation/obviousness.
  • Claim terms that construction narrows away from the accused product.
  • Prior art that discloses the core limitation in one or more references.

What is the likely basis for Apotex’s defense strategy?

Featured snippet answer: Apotex’s defense in 1:18-cv-03404 is typically built around non-infringement and invalidity: Apotex argues either the product does not meet claim limitations (including formulation/process differences) or the asserted patents are invalid (anticipation, obviousness, lack of enablement, or improper subject matter).

Defense vectors that matter for business risk

• Product non-infringement: whether formulation or method differences avoid literal infringement.
• Design-around feasibility: if claim limitations are narrow, Apotex may win by showing a small but decisive difference.
• Validity leverage: if key claims are vulnerable to a single prior art disclosure or a strong obviousness combination.
• Procedural leverage: partial dismissals or summary judgment on non-infringement can materially reduce exposure.

What settlement or judgment risk exists for UCB in this case?

Featured snippet answer: In Hatch-Waxman patent suits, settlement risk is driven by (i) the probability that UCB’s asserted claims will survive claim construction and dispositive motion and (ii) whether Apotex can credibly launch “at risk” absent a settlement. Many cases resolve through a consent judgment or settlement terms that define permitted launch timing.

What settlement terms typically control?

• Launch date (fixed or linked to patent status)
• License scope (if granted)
• Royalty structure (if included)
• Interim supply limits
• Stipulations regarding patent expiration or exclusivity carve-outs
• Agreement not to further challenge certain claims or patents

How does this case affect FDA entry timing for Apotex generics?

Featured snippet answer: The litigation in 1:18-cv-03404 affects the generic’s ability to enter the market during the statutory stay period. If UCB’s patents remain in force and infringement is upheld, Apotex’s entry is delayed. If Apotex clears the asserted patents, FDA market entry can proceed once regulatory and any remaining patent barriers are cleared.

What matters for launch sequencing?

• Whether the FDA approval is already in place
• Whether the statutory stay remains in effect
• Whether any additional listed patents are asserted later or separate Orange Book barriers exist
• Whether settlement conditions override litigation timing

Which other challenges are typically paired with this kind of UCB vs generic litigation?

Featured snippet answer: Cases like 1:18-cv-03404 often coexist with:

• Additional suits against other generic manufacturers
• Related ITC or state-law disputes (less common in pure Hatch-Waxman disputes)
• Follow-on suits targeting later-manufacturing revisions or additional dosages

UCB vs Apotex: how does the case compare with other UCB generics disputes?

Featured snippet answer: Compared with other UCB v. generic suits, the core differentiator is the claim set and product-specific limitations that determine claim construction outcomes. The competitive impact is determined by the “last-to-expire” patents that survive dispositive motion and by whether settlement assigns a defined entry date.

What comparative analysis should focus on?

• Number of asserted patents and their categories
• Claim construction outcomes: whether courts adopt the brand’s narrow reading
• Validity outcomes: which specific prior art references are credited
• Settlement coverage: whether it includes all asserted patents or only some

Key case-risk signals for investors, licensing teams, and R&D planners

Featured snippet answer: The business exposure in 1:18-cv-03404 tracks with whether UCB’s asserted claims are narrowed into non-infringement territory or invalidation territory during claim construction and dispositive motion. The presence of multiple asserted patents reduces launch risk only if the surviving claims anchor the “last-to-expire” date and remain enforceable.

Practical IP and regulatory actions that follow from the case type

• Build product design-around analysis tied to the claim limitations adopted in Markman
• Track any amendments to asserted claims and any late-stage stipulations
• Map litigation outcomes to Orange Book “last-to-expire” and any unasserted listed patents

Key Takeaways

1. UCB v. Apotex (1:18-cv-03404) is a Hatch-Waxman-style infringement/invalidity dispute that drives the generic’s market entry timing through patent enforceability.
2. Case strength hinges on how claim construction narrows infringement and whether asserted claims survive non-infringement and invalidity challenges.
3. Commercial impact depends on whether any settlement or consent judgment fixes a launch date or permits earlier “at risk” entry.
4. The critical metric for launch risk is the surviving “last-to-expire” patent set, not the number of asserted patents at filing.

FAQs

1) What is the standard claim-construction impact in UCB vs generic patent cases?
Claim construction can narrow functional language and reduce infringement exposure if the generic’s measurable product attributes fall outside the construed limitation.

2) Does a settlement in 1:18-cv-03404 automatically invalidate patents?
Settlements in Hatch-Waxman cases more often define launch rights contractually than they formally invalidate patents.

3) How does this case affect “at-risk” launch for Apotex?
If the case ends with an injunction or settlement terms limiting entry, Apotex cannot lawfully launch until conditions are satisfied. If UCB loses asserted claims, entry timing can move earlier subject to any remaining listed patents.

4) What patent categories most often survive in formulation/process-driven UCB litigation?
Claims with specific, technically anchored limitations tied to measurable product attributes tend to be more defensible than broadly functional formulations.

5) Are biosimilar risks relevant to a UCB vs Apotex case number like this?
Only if the underlying product is biologic and implicated by the asserted patents. Hatch-Waxman Apotex-style cases typically concern small-molecule drugs under ANDA rather than biosimilars under BLA pathways.

References

1. Court docket for UCB, Inc. v. Apotex Inc., No. 1:18-cv-03404.